RLMD
Relmada Therapeutics Inc
NASDAQ: RLMD · HEALTHCARE · BIOTECHNOLOGY
$7.52
+2.04% today
Updated 2026-04-30
Market cap
$759.40M
P/E ratio
—
P/S ratio
9,001.90x
EPS (TTM)
$-1.45
Dividend yield
—
52W range
$0 – $8
Volume
2.1M
Relmada Therapeutics Inc (RLMD) Financial statements
SEC filings — annual and quarterly data.
Profit margin
0.00%
Operating margin
0.00%
ROE
-25.60%
ROA
-14.40%
Debt/equity
—
Margin trends — annual
Gross margin Operating margin Profit margin
| Year | Revenue | Net income | Gross margin | Op. margin | Profit margin |
|---|---|---|---|---|---|
| 2012 | $7941.00 | $-12052.00 | 26.97% | -151.77% | -151.77% |
| 2013 | $5129.00 | $-45015.00 | 21.31% | -877.66% | -877.66% |
| 2014 | — | $-20.80M | — | — | — |
| 2015 | — | $-20.80M | — | — | — |
| 2016 | — | $-2.98M | — | — | — |
| 2017 | — | $-6.29M | — | — | — |
| 2018 | $0.00 | $-8.96M | — | — | — |
| 2019 | — | $-15.01M | — | — | — |
| 2020 | $0.00 | $-59.46M | — | — | — |
| 2021 | $0.00 | $-125.75M | — | — | — |
| 2022 | $0.00 | $-157.04M | — | — | — |
| 2023 | $0.00 | $-98.79M | — | — | — |
| 2024 | $0.00 | $-79.98M | — | — | — |
| 2025 | $0.00 | $-57.39M | — | — | — |